Avoro Ventures — Full Portfolio
2 tracked investments · listed companies and verified rows first
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Board seatBehzad Aghazadeh· per SEC Form D · $100M raise · filed Mar 2025
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalVivo CapitalOrbiMed
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Board seatBehzad Aghazadeh· per SEC Form D · $100M raise · filed Apr 2021
Co-investorsAndreessen HorowitzOrbiMedAvoro Capital AdvisorsMenlo VenturesRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.